BCG vaccine mediated reduction in the MHC-II expression of macrophages and dendritic cells is reversed by activation of Toll-like receptors 7 and 9. Academic Article uri icon

Overview

abstract

  • Tuberculosis is a major cause of death in mankind and BCG vaccine protects against childhood but not adult tuberculosis. BCG avoids lysosomal fusion in macrophages decreasing peptides required for activating CD4 T cells and Th1 immunity while suppressing the expression of MHC-II by antigen presenting cells (APCs). An in vitro model of antigen presentation showed that ligands for TLR-9, 7, 4 and 1/2 increased the ability of APCs to present antigen-85B of BCG to CD4 T cells, which correlated with an increase in MHC-II expression. TLR-activation led to a down-regulation of MARCH1 ubiquitin ligase which prevents the degradation of MHC-II and decreased IL-10 also contributed to an increase in MHC-II. TLR-activation induced up-regulation of MHC-II was inhibited by the blockade of IRAK, NF-kB, and MAPKs. TLR-7 and TLR-9 ligands had the most effective adjuvant like effect on MHC-II of APCs which allowed BCG vaccine mediated activation of CD4 T cells.

publication date

  • December 11, 2013

Research

keywords

  • BCG Vaccine
  • CD4-Positive T-Lymphocytes
  • Dendritic Cells
  • Macrophages
  • Mycobacterium tuberculosis
  • Toll-Like Receptor 7
  • Toll-Like Receptor 9
  • Tuberculosis

Identity

PubMed Central ID

  • PMC4096037

Scopus Document Identifier

  • 84891365024

Digital Object Identifier (DOI)

  • 10.1016/j.cellimm.2013.11.007

PubMed ID

  • 24384074

Additional Document Info

volume

  • 287

issue

  • 1